How Netris’ dependence receptor programs kill cancer stem cells missed by other drugs
Netris Pharma S.A.S. is aiming to boost rates and durations of responses to immunotherapies by targeting a population of slow-growing cells these therapies leave behind. The biotech’s mAbs restore the pro-apoptotic function of dependence receptors, and could be useful in combinations to root out slowly proliferating cancer stem cells.
By February, the company expects to have data from a Phase I trial of NP137 in solid tumors that will help determine the dose to take forward in combination studies.
When bound to their ligands, dependence receptors stimulate pathways involved in cell survival, migration or differentiation. When ligand-bound, some